A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated … (NCT05331885) | Clinical Trial Compass
TerminatedPhase 3
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Stopped: The study was terminated due to administrative reasons
Belgium, France, Greece24 participantsStarted 2022-09-02
Plain-language summary
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
Who can participate
Age range
12 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Colonized with Staphylococcus aureus;
. Expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.
Exclusion criteria
. Staphylococcal disease at randomisation;
. Lung injury score consistent with pneumonia;
. Chronic tracheostomy patients;
. The study subject is moribund
. Receipt of anti- S. aureus systemic antibiotics
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was terminated before completing — can you find out why it was stopped early, and what that means for the safety or effectiveness of this antibody treatment?
2Since this was a Phase 3 trial studying a monoclonal antibody against Staphylococcus aureus alpha toxin in patients on mechanical ventilation, is there any published data from this study that might still be relevant to my situation or treatment options?
3The trial was measuring all-cause pneumonia rates over 30 days after a single dose — based on whatever results were collected before termination, is there any signal about whether this antibody approach showed promise or raised concerns?
4Are there other active trials or standard treatments targeting Staphylococcus aureus infections in ventilated patients that might be a better path for me to explore given that this study is no longer enrolling?
5Since this trial involved mechanically ventilated patients specifically, does my current condition or care setting make me a candidate for any similar investigational or approved therapies aimed at preventing ventilator-associated pneumonia?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of nosocomial all-cause pneumonia through 30 days post dose